|
GB202103673D0
|
|
Combination therapy for cancer
|
|
GB201914153D0
|
|
Foxp3 Polypeptides
|
|
GB201908012D0
|
|
TGF-Beta vaccine
|
|
GB201819188D0
|
|
Foxp3 polypeptides
|
|
CN111372656A
|
|
Enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC)
|
|
GB201818576D0
|
|
Arginase 2 polypeptides
|
|
GB201815549D0
|
|
Arginase1 polypeptides
|
|
GB201806575D0
|
|
Vaccine to enhance adcc
|
|
GB201719561D0
|
|
Vaccine to enhance ADCC
|
|
EP3532487A1
|
|
New pdl2 compounds
|
|
CN109890399A
|
|
Immunogenicity arginine enzyme peptide
|
|
US2020339659A1
|
|
Pdl1 peptides for use in cancer vaccines
|
|
CA3026572A1
|
|
Calr and jak2 vaccine compositions
|
|
US2019343940A1
|
|
Combination therapy against cancer
|
|
AU2016322506A1
|
|
Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
|
|
GB201610018D0
|
|
Combination
|
|
GB201603805D0
|
|
Combination
|
